Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
A study has suggested that the use of weight-loss jabs may be associated with wider health benefits, including a lower risk ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it becomes available to the public, a Monday study found. Obese adults who ...
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
About 10 million Americans believe they have benefited from the injections ... approved to treat obesity — Wegovy, Zepbound, or Saxenda. Other common weight-loss medications like Ozempic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback